This week's data shows researchers are actively testing drug combinations that may help keep lungs working longer for people with IPF (a disease where lung tissue slowly scars over time).
FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.
This is a computer model result — not a prescription. Always talk to your doctor before changing anything.
This week our database grew to 3,873 studies and 1,205 clinical trials (real-world tests of treatments in people) focused on IPF. Most of this week's new papers covered general health topics, but the big IPF work is happening behind the scenes in ongoing trials. Researchers worldwide — especially in Russia, China, and Korea — are publishing more IPF-related work than ever before, which means more eyes are on this disease.
Our AI tested thousands of drug combinations to find what might best protect lung capacity. The winning combination kept FVC (a simple breath test that measures how much air your lungs can push out) at 98.1%. That is very close to normal, which is exciting. The mix included seven treatments, among them metformin (a common diabetes pill being studied for lung scarring) and pamrevlumab (a drug designed to block scarring signals).
One question to ask your lung doctor at your next visit: "Are there any clinical trials testing combination treatments for IPF that I might qualify for right now?"